Histaminergic Basis of Central Fatigue in Multiple Sclerosis - A Novel Approach
NCT03266965 is a phase 1 interventional trial sponsored by University of Miami. As of 21 Nov 2026, it is completed. It studies Carbidopa in Multiple Sclerosis. The registry lists an enrollment of 18 participants at 1 site in 1 country. The registry lists a start date of 23 Mar 2018 and a primary completion date of 7 Aug 2020.
Key facts
Registry attributes as recorded on the ClinicalTrials.gov study record.
| Field | Value |
|---|---|
| Registry ID | NCT03266965 |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional trial |
| Lead sponsor | University of Miami |
| Enrollment | 18 |
| Registered sites | 1 |
| Countries | 1 |
| Conditions | Multiple Sclerosis |
| Drugs | Carbidopa |
| Start | 23 Mar 2018 |
| Primary completion | 7 Aug 2020 |
| Study completion | 7 Aug 2020 |
| Last update posted | 8 Oct 2020 |
Registered summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- Kottil Rammohan, MD
University of Miami
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- University of Miami
Miami
United States, by state
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Questions about NCT03266965
Each answer restates registry values shown on this page.
What is NCT03266965?
NCT03266965 is a phase 1 interventional trial sponsored by University of Miami. It studies Carbidopa in Multiple Sclerosis.
Who leads NCT03266965?
The registry names Kottil Rammohan, MD (principal investigator, University of Miami) as the overall official.
Where does NCT03266965 run?
The registry lists 1 site in 1 country. Every site with a stated country is in one country: United States.
Which drugs does NCT03266965 study?
The registered drug and biological interventions are Carbidopa.
When did NCT03266965 end?
The registry lists a primary completion date of 7 Aug 2020 and a study completion date of 7 Aug 2020. The sponsor last updated the record on 8 Oct 2020.
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.